Endpoints News Apr 2, 2026 Novo and Lilly battle over GLP-1 claims only a head-to-head trial can answer
Endpoints News Apr 2, 2026 Eli Lilly's chief technology officer retires after 35 years; Astellas strategy exec resigns
Endpoints News Apr 1, 2026 Lilly wins approval of anti-obesity pill orforglipron, setting up new battle with Novo
Endpoints News Mar 20, 2026 UK’s NICE revisits Lilly, Eisai Alzheimer's drugs under new pricing threshold
Endpoints News Mar 19, 2026 Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
Endpoints News Mar 12, 2026 Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound
Endpoints News Mar 11, 2026 Lilly plots GLP-1 pill production boost in China, $500M pledge to South Korea
Endpoints News Mar 6, 2026 Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
Endpoints News Feb 24, 2026 Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
Endpoints News Feb 23, 2026 Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial